Oppenheimer initiated coverage of Aprea Therapeutics (APRE) with an Outperform rating and $5 price target The firm cites the potential of the company’s WEE1 inhibitor APR-1051 and the stock’s “sizable valuation discount” relative to peers for the buy rating. 2026 could be a “breakout year” for WEE1 as a target, with potentially pivotal data and a registrational filing for Zentalis’ azenosertib, the analyst tells investors in a research note. Oppenheimer says APR-1051 is only the second WEE1 inhibitor being tested clinically as a monotherapy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APRE:
- Aprea Therapeutics files to sell 74.35M shares of common stock for holders
- Aprea Therapeutics: Positive Read‑Through From Zentalis and Improving WEE1 Sentiment Support Buy Rating and $5 Target
- Aprea Therapeutics Raises $30M to Advance Oncology Pipeline
- Aprea Therapeutics price target lowered to $1.20 from $4 at H.C. Wainwright
- Aprea Therapeutics Announces $30 Million Private Placement